- Home
- CRVS vs JGH Comparison
CRVS vs JGH Comparison
Compare CRVS & JGH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRVS
- JGH
- Stock Information
- Founded
- CRVS 2014
- JGH 2014
- Country
- CRVS United States
- JGH United States
- Employees
- CRVS N/A
- JGH N/A
- Industry
- CRVS Biotechnology: Pharmaceutical Preparations
- JGH Investment Managers
- Sector
- CRVS Health Care
- JGH Finance
- Exchange
- CRVS Nasdaq
- JGH Nasdaq
- Market Cap
- CRVS 305.4M
- JGH 292.3M
- IPO Year
- CRVS 2016
- JGH N/A
- Fundamental
- Price
- CRVS $4.11
- JGH $13.13
- Analyst Decision
- CRVS Strong Buy
- JGH
- Analyst Count
- CRVS 4
- JGH 0
- Target Price
- CRVS $15.00
- JGH N/A
- AVG Volume (30 Days)
- CRVS 1.2M
- JGH 73.9K
- Earning Date
- CRVS 08-05-2025
- JGH 01-01-0001
- Dividend Yield
- CRVS N/A
- JGH 9.85%
- EPS Growth
- CRVS N/A
- JGH N/A
- EPS
- CRVS N/A
- JGH N/A
- Revenue
- CRVS N/A
- JGH N/A
- Revenue This Year
- CRVS N/A
- JGH N/A
- Revenue Next Year
- CRVS N/A
- JGH N/A
- P/E Ratio
- CRVS N/A
- JGH N/A
- Revenue Growth
- CRVS N/A
- JGH N/A
- 52 Week Low
- CRVS $1.78
- JGH $10.36
- 52 Week High
- CRVS $10.00
- JGH $12.85
- Technical
- Relative Strength Index (RSI)
- CRVS 53.94
- JGH 71.02
- Support Level
- CRVS $3.79
- JGH $13.03
- Resistance Level
- CRVS $4.31
- JGH $13.23
- Average True Range (ATR)
- CRVS 0.29
- JGH 0.09
- MACD
- CRVS 0.00
- JGH 0.03
- Stochastic Oscillator
- CRVS 72.64
- JGH 85.71
About CRVS Corvus Pharmaceuticals Inc.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).
About JGH Nuveen Global High Income Fund of Beneficial Interest
Nuveen Global High Income Fund operates as a diversified closed-end management investment company. The fund's investment objective is to provide a high level of current income. Its securities include U.S. high-yield bonds; non-U.S. high-yield bonds from developed and emerging markets; and other income-producing investments such as preferred and convertible securities.